Enzolytics Inc (ENZC)

[Mutat]

your Daily read with a lot of info.

Enzolytics, Inc. Discusses the Significance and Revenue Potential of Its Therapeutic Platforms with The Stock Day Podcast
May 16, 2022, 7:00 AM MDT
Share this article
Phoenix, Arizona--(Newsfile Corp. - May 16, 2022) - The Stock Day Podcast
welcomed Enzolytics, Inc. (ENZC) ("the Company"), a drug development company
committed to commercializing its proprietary proteins and monoclonal
antibodies to treat debilitating infectious diseases. Director and COO of the
Company, Dr. Gaurav Chandra, joined Stock Day host Everett Jolly.

"Could you tell us about IPF Immune™ and the success you're hoping it will
bring to the Company?", asked Jolly to begin the interview. "IPF Immune™ is a
science-backed immune modulator that helps strengthen the body's defenses
against viruses or other pathogens," explained Dr. Chandra, adding that the
product stimulates the body's natural immune system, without producing any
side effects. "It works as an immune booster that increases the ability of the
immune system to fight infections, and in addition it enhances recovery and
reduces the recovery period after an illness."

"While we have already launched IPF Immune™ in the United States, we are also
launching the product in Europe and Canada in the next three months,"
continued Dr. Chandra, noting the revenue potential of this product.

Dr. Chandra then elaborated on the significance of IPF Immune™, citing
positive results during testing against the CoronaVirus (SARS-CoV-2) strain
229e. "It actually showed comparable efficacy, but with 24 times lower
toxicity than the widely used antiviral, Tamiflu," said Dr. Chandra, noting
the product's additional applications. Additionally, he said that our
preliminary studies with IPF-Immune have demonstrated significant in-vitro
neutralization activity against Adenovirus. "In the next couple of weeks, we
will be sharing efficacy data with our shareholders."

"Do you have any revenue projections for IPF Immune™ going forward?", asked
Jolly. "We do have revenue projections, and they are extremely healthy
projections," shared Dr. Chandra. "The immune modulator market is large and
growing," he added. "It's a $50 billion nutritional supplement market, so we
expect significant revenues in the upcoming year."

Jolly commented on the Company's numerous product platforms, including their
patented and clinically tested compound, ITV-1 (Immune Therapeutic Vaccine-1),
as well as their monoclonal antibody program, and asked what makes the Company
so special. "We have identified the conserved immutable targets in about 20
viruses, and then we went a bit further," said Dr. Chandra. "We built AI-based
three-dimensional models of these immutable targets and established linearity,
neutralization by antibodies or accessibility by antibodies, before moving
forward to develop monoclonal antibodies that target these specific
sequences."

"We actually did the same thing for HIV viruses," he continued. "We identified
8 conserved immutable targets," said Dr. Chandra. "The virus can mutate many
times, but since these are conserved it will remain unchanged," he explained.
"The resulting monoclonal antibodies that we have created are universal,
durable, broadly utilizing, and will remain unaffected by mutations or viruse
escape."

Dr. Chandra then discussed the importance of AI-driven diagnostics. "We are
discussing partnerships with diagnostic companies that have a track record of
getting diagnostics tests through Regulatory approval and distributing these
diagnostic tests for clinical use.," said Dr. Chandra. "As viruses mutate, the
diagnostic test for them have to be modified to identify each mutant of the
virus," he said. "But since the targets we have identified remain unchanged,
if those target sites are used to diagnose the virus, then you have a test
that is universally applicable even for mutants of the viruses."

Talking about AI-driven prognostics he said that there are documented studies
showing better prognosis and clinical outcomes in patients with antibodies to
the AI-identified conserved targets. Enzolytics is also discussing a potential
partnership to develop a prognostic test that predicts immune response before
receiving a vaccine or antiviral therapy.

"Since we have the capability of identifying conserved targets, we are
actually working to be a part of consortiums that are looking to prevent the
next global pandemic, and that is very exciting for us," shared Dr. Chandra.
"The AI platform significantly cuts down the time for our drug discovery and
development."

"Where is Enzolytics at with collaborations moving forward?", asked Jolly. "At
Enzolytics, we build a product and put effort into R&D, and then we intend to
partner with a larger entity, a large pharmaceutical company, that can take it
through the clinical stages quickly," said Dr. Chandra. "We need to make sure
our products reach patients as soon as possible."

"Have you considered where your valuation may end up six months to two years
from now?", asked Jolly. "The market cap is not reflecting the full potential
of Enzolytics," said Dr. Chandra, noting the significant market for each of
the Company's products. "The next product that we have is ITV-1, which is an
HIV therapeutic and has actually cleared Phase III clinical trials and is
preparing for introduction into two markets," he explained. "The African
market is a significant market because 65% of about 34 to 37 million HIV
infected individuals live in Africa."

"We will also be introducing this product into Europe, and are currently
awaiting certification under the European Medical Agency," shared Dr. Chandra.

"The global monoclonal antibody market is significant; we are looking at a
$144 billion market," continued Dr. Chandra. "We have four monoclonal
antibodies for infectious diseases that are in clinical development as we
speak."

"As you can imagine, although the market is not reflecting the actual market
cap of the company, in the next six months to one year we anticipate a
monumental shift in the position of the company as our clinical products start
coming to the market ," said Dr. Chandra.

To close the interview, Dr. Chandra encouraged listeners and shareholders to
keep up to date with the Company's updates and current projects as they
continue to make significant progress across its multiple therapeutic
platforms.

To hear Dr. Chandra's entire interview, follow the link to the podcast here:
https://audioboom.com/posts/8084060-enzolytics-inc-discusses-the-significance-and-revenue-potential-of-its-therapeutic-platforms-wi

Investors Hangout is a proud sponsor of "Stock Day," and Stock Day Media
encourages listeners to visit the company's message board at
https://investorshangout.com/

About Enzolytics, Inc.

Enzolytics, Inc. is a drug development company committed to commercializing
its proprietary proteins and monoclonal antibodies to treat debilitating
infectious diseases. The Company is advancing multiple therapeutics targeting
numerous infectious diseases. One patented and clinically tested compound,
ITV-1 (Immune Therapeutic Vaccine-1), is a suspension of Inactivated Pepsin
Fraction (IPF), covered by U.S. Patent Nos. 8,066,982 and 7,479,538. Studies
have shown it to be effective in treating HIV/AIDS. ITV-1 has also been shown
to modulate the immune system.

The Company is also implementing its proprietary technology to produce fully
human monoclonal antibodies (mAbs) against infectious diseases, including HIV,
rabies, influenza A, influenza B, tetanus, and diphtheria. In addition, its
proprietary methodology, covered in its pending U.S./PCT Patent Application
for producing fully human monoclonal antibodies, is currently employed to
produce monoclonal antibody therapeutics for numerous infectious diseases,
including the CoronaVirus (SARS-CoV-2) and HTLV-1.

Safe Harbor Statement: This news release contains forward-looking statements
that involve risks and uncertainties associated with financial projections,
budgets, milestone timelines, clinical development, regulatory approvals, and
other risks described by Enzolytics, Inc. from time to time in its periodic
reports filed with the SEC. ITV-1 is not approved by the U.S. Food and Drug
Administration or by any comparable regulatory agencies elsewhere in the
world.

While Enzolytics, Inc. believes that the forward-looking statements and
underlying assumptions contained therein are reasonable, any of the
assumptions could be inaccurate, including, but not limited to, the ability of
Enzolytics to establish the efficacy of its therapeutics in the treatment of
any disease or health condition, the development of studies and strategies
leading to commercialization of its therapeutics in the United States, the
obtaining of funding required to carry out the development plan, the
completion of studies and tests on time or at all, and the successful outcome
of such studies or tests. Therefore, there can be no assurance that the
forward-looking statements included in this release will prove to be accurate.

Such forward-looking statements are based on current expectations. They
involve inherent risks and uncertainties, including factors that could delay,
divert or change any of the statements made, and cause actual outcomes and
results to differ materially from current expectations. No forward-looking
statement can be guaranteed. These forward-looking statements are made as of
the date of this press release. The Company expressly disclaims any intention
or obligation to update the forward-looking statements or update the reasons
why actual results could differ from those projected in the forward-looking
statements.

I.R. contact:
Enzolytics Inc.

Company Contact:
Enzolytics, Inc.

Texas A&M Institute for Preclinical Studies
Enzolytics, Inc.
800 Raymond Stotzer Parkway
College Station, Texas 77843-4478